Interventions for tic disorders: An updated overview of systematic reviews and meta analyses

2020 ◽  
Vol 287 ◽  
pp. 112905 ◽  
Author(s):  
Chunsong Yang ◽  
Xiao Cheng ◽  
Qiyunrui Zhang ◽  
Dan Yu ◽  
Jiayuan Li ◽  
...  
2016 ◽  
Vol 63 ◽  
pp. 239-255 ◽  
Author(s):  
Chunsong Yang ◽  
Zilong Hao ◽  
Cairong Zhu ◽  
Qin Guo ◽  
Dezhi Mu ◽  
...  

2017 ◽  
Vol 6 (1) ◽  
Author(s):  
Efthymia Prousali ◽  
Asimina Mataftsi ◽  
Nikolaos Ziakas ◽  
Andreas Fontalis ◽  
Periklis Brazitikos ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Xia-tian Zhang ◽  
Xin-yi Li ◽  
Chen Zhao ◽  
Ye-yin Hu ◽  
Yi-yi Lin ◽  
...  

Objectives. To review the evidence of acupuncture for acute and preventive treatment of migraine for further awareness of the effect of acupuncture for migraine. Design. An overview of systematic reviews and meta-analyses (SR/MAs) for randomized controlled trials. Material and Methods. We searched PubMed, Embase, the Cochrane Library, China Knowledge Resource Integrated Database, VIP Chinese Journal Full Text Database, WANFANG Data, and China Biology Medicine disc from their establishment to May 27, 2018. SR/MAs of randomized controlled trials comparing the effect of the acupuncture intervention with another treatment control in migraine patients were included. Results. 428 SRs were identified, and 15 of them were included. Only 4 SR/MAs were assessed by GRADE, which showed certainty of most evidence being low or very low. Assessed by AMSTAR-2, fourteen was critically low rating overall confidence in the results, and 1 was low rating overall confidence in the results. Evidence suggested that acupuncture has a significant advantage of pain improvement, efficacy, and safety relative to blank control, sham acupuncture, or drug treatment, but some of these results are contradictory. Conclusions. We found that acupuncture on treating migraine has the advantage for pain improvement and safety, but the quality of SR/MAs of acupuncture for migraine remains to be improved.


2014 ◽  
Vol 22 (4) ◽  
pp. 787-800 ◽  
Author(s):  
Jing Luo ◽  
Hao Xu ◽  
Guoyan Yang ◽  
Yu Qiu ◽  
Jianping Liu ◽  
...  

Solar Energy ◽  
2019 ◽  
Vol 186 ◽  
pp. 291-299 ◽  
Author(s):  
Gihan Samarasinghe ◽  
Malgorzata Lagisz ◽  
Mattheos Santamouris ◽  
Komali Yenneti ◽  
Anir Kumar Upadhyay ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (8) ◽  
pp. e029828 ◽  
Author(s):  
Kevin M Trentino ◽  
Shannon L Farmer ◽  
Frank M Sanfilippo ◽  
Michael F Leahy ◽  
James Isbister ◽  
...  

IntroductionThere has been a significant increase in the number of systematic reviews and meta-analyses of randomised controlled trials investigating thresholds for red blood cell transfusion. To systematically collate, appraise and synthesise the results of these systematic reviews and meta-analyses, we will conduct an overview of systematic reviews.Methods and analysisThis is a protocol for an overview of systematic reviews. We will search five databases: MEDLINE, Embase, Web of Science Core Collection, PubMed (for prepublication, in process and non-Medline records) and Google Scholar. We will consider systematic reviews and meta-analyses of randomised controlled trials evaluating the effect of haemoglobin thresholds for red blood cell transfusion on mortality. Two authors will independently screen titles and abstracts retrieved in the literature search and select studies meeting the eligibility criteria for full-text review. We will extract data onto a predefined form designed to summarise the key characteristics of each review. We will assess the methodological quality of included reviews and the quality of evidence in included reviews.Ethics and disseminationFormal ethics approval is not required for this overview as we will only analyse published literature. The findings of this study will be presented at relevant conferences and submitted for peer-review publication. The results are likely to be used by clinicians, policy makers and developers of clinical guidelines and will inform suggestions for future systematic reviews and randomised controlled trials.PROSPERO registration numberCRD42019120503.


BMC Medicine ◽  
2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Kevin M. Trentino ◽  
Shannon L. Farmer ◽  
Michael F. Leahy ◽  
Frank M. Sanfilippo ◽  
James P. Isbister ◽  
...  

Geriatrics ◽  
2020 ◽  
Vol 5 (1) ◽  
pp. 17
Author(s):  
Richard Ofori-Asenso ◽  
Ken Lee Chin ◽  
Berhe W. Sahle ◽  
Mohsen Mazidi ◽  
Andrew R. Zullo ◽  
...  

We performed an overview of systematic reviews and meta-analyses to summarize available data regarding the association between frailty and all-cause mortality. Medline, Embase, CINAHL, Web of Science, PsycINFO, and AMED (Allied and Complementary Medicine) databases were searched until February 2020 for meta-analyses examining the association between frailty and all-cause mortality. The AMSTAR2 checklist was used to evaluate methodological quality. Frailty exposure and the risk of all-cause mortality (hazard ratio [HR] or relative risk [RR]) were displayed in forest plots. We included 25 meta-analyses that pooled data from between 3 and 20 studies. The number of participants included in these meta-analyses ranged between <2000 and >500,000. Overall, 56%, 32%, and 12% of studies were rated as of moderate, low, and critically low quality, respectively. Frailty was associated with increased risk of all-cause mortality in 24/24 studies where the HR/RRs ranged from 1.35 [95% confidence interval (CI) 1.05–1.74] (patients with diabetes) to 7.95 [95% CI 4.88–12.96] (hospitalized patients). The median HR/RR across different meta-analyses was 1.98 (interquartile range 1.65–2.67). Pre-frailty was associated with a significantly increased risk of all-cause mortality in 7/7 studies with the HR/RR ranging from 1.09 to 3.65 (median 1.51, IQR 1.38–1.73). These data suggest that interventions to prevent frailty and pre-frailty are needed.


Sign in / Sign up

Export Citation Format

Share Document